Table 3.
Pediatric renal transplant patients with biopsy-proven human polyomavirus type 1 (BKV) nephropathy
| Authors | Center BKV nephropathy rate (%) | Pt. number(<20 years) | Age (years) | Time posttransplant (months) | Treatment | Outcome; last creatinine |
|---|---|---|---|---|---|---|
| Alexander et al. [14] | 7.7 | 4 | N/A | 38 | ↓ ImmunoSup | Stable graft function; Creat = 125 μM/l |
| N/A | 24 | ↓ ImmunoSup + cidofovir | Graft loss within 12 months | |||
| N/A | 12 | ↓ ImmunoSup + cidofovir | Deteriorating graft function; Creat = 240 μM/l | |||
| N/A | 6 | ↓ ImmunoSup | Stable graft function; Creat = 100 μM/l | |||
| Araya et al. [35] | N/A | 3 | 8 | 48 | ↓ ImmunoSup + cidofovir | Graft function improved; Creat = 115 μM/l |
| 17 | 19 | ↓ ImmunoSup + cidofovir | Creat decreased from peak; Creat = 194 μM/l | |||
| 19 | 4 | ↓ ImmunoSup + cidofovir | Graft function near baseline; Creat = 88 μM/l | |||
| Comoli et al. [38] | N/A | 3 | 9 | 32 | Stable graft function; Creat = 106 μM/l | |
| 15 | 3 | Stable graft function; Creat = 123 μM/l | ||||
| 18 | 1 | Stable graft function; Creat = 132 μM/l | ||||
| Ginevri et al. [15] | 3 | 3 | N/A | 32 | ↓ ImmunoSup + cidofovir | Graft loss |
| N/A | 1 | ↓ ImmunoSup | Stable graft function; Creat = 132 μM/l | |||
| N/A | 4 | ↓ ImmunoSup | Stable graft function; Creat = 123 μM/l | |||
| Herman et al. [17] | 4.3 | 2 | 13 | 6 | ↓ ImmunoSup + CMV Rx | Stable graft function; Creat = 114 μM/l |
| 8 | 14 | ↓ ImmunoSup + cidofovir | Stable graft function; Creat = 106 μM/l | |||
| Hymes et al. [36] | 6.6 | 8 | 12 ± 4 | 22 ± 13 | ↓ ImmunoSup + cidofovir (7/8) | Stable graft function in 4/8 |
| ↓ ImmunoSup (1/8) | Deteriorating graft function in 4/8; Creat = 150, 211, 97, 238 μM/l, respectively | |||||
| Muller et al. [37] | 3 | 1 | N/A | N/A | ↓ ImmunoSup + leflunomide | Graft loss |
| Smith et al. [26] | N/A | 6 | 16 | 14 | ↓ ImmunoSup | Creat decreased from peak; Creat = 211 μM/l |
| 3 | 44 | ↓ ImmunoSup | Stable graft function; Creat = 115 μM/l | |||
| 8 | 47 | ↓ ImmunoSup | Deteriorating graft function; Creat = 282 μM/l | |||
| 5 | 4 | ↓ ImmunoSup | Stable graft function; Creat = 79 μM/l | |||
| 13 | 16 | ↓ ImmunoSup | Deteriorating graft function; Creat = 158 μM/l | |||
| 13 | 10 | ↓ ImmunoSup | Deteriorating graft function; Creat = 176 μM/l | |||
| Vats et al. [33] | N/A | 2 | 4 | 22 | ↓ ImmunoSup + cidofovir | Creat decreased from peak; Creat = 150 μM/l |
| 10 | 12 | ↓ ImmunoSup + cidofovir | Creat decreased from peak; Creat = 158 μM/l |
N/A not available, CMV cytomegalovirus, Pt patient, ImmunoSup Immunosuppression